Diabetic Foot Ulcers – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Diabetic Foot Ulcers – Pipeline Review, H1 2017’, provides an overview of the Diabetic Foot Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers

– The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ANP Technologies Inc

Anterogen Co Ltd

Boston Therapeutics Inc

CardioVascular BioTherapeutics Inc

Celgene Corp

Chrysalis BioTherapeutics Inc

CytoTools AG

EyeGene Inc

FirstString Research Inc

Genentech Inc

GlaxoSmithKline Plc

Human Stem Cells Institute

Izun Pharmaceuticals Corp

Lakewood-Amedex Inc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Oneness Biotech Co Ltd

Osiris Therapeutics Inc

Pherecydes Pharma SA

RMB-Research GmbH

Serodus ASA

Stempeutics Research Pvt Ltd

Stratatech Corp

TechnoPhage SA

Theravasc Inc

Topadur Pharma AG

USV Pvt Ltd

viDA Therapeutics Inc

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Foot Ulcers - Overview 8

Diabetic Foot Ulcers - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Diabetic Foot Ulcers - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 27

ANP Technologies Inc 27

Anterogen Co Ltd 27

Boston Therapeutics Inc 28

CardioVascular BioTherapeutics Inc 28

Celgene Corp 29

Chrysalis BioTherapeutics Inc 29

CytoTools AG 30

EyeGene Inc 30

FirstString Research Inc 31

Genentech Inc 31

GlaxoSmithKline Plc 32

Human Stem Cells Institute 32

Izun Pharmaceuticals Corp 33

Lakewood-Amedex Inc 33

MediWound Ltd 34

NovaLead Pharma Pvt Ltd 34

Oneness Biotech Co Ltd 35

Osiris Therapeutics Inc 35

Pherecydes Pharma SA 36

RMB-Research GmbH 36

Serodus ASA 37

Stempeutics Research Pvt Ltd 37

Stratatech Corp 38

TechnoPhage SA 38

Theravasc Inc 39

Topadur Pharma AG 39

USV Pvt Ltd 40

viDA Therapeutics Inc 40

ViroMed Co Ltd 41

Diabetic Foot Ulcers - Drug Profiles 42

3K3A-APC - Drug Profile 42

ALLO-ASC - Drug Profile 44

ANP-017 - Drug Profile 46

AP-185 - Drug Profile 47

APO-2 - Drug Profile 48

AUP-16 - Drug Profile 49

becaplermin biosimilar - Drug Profile 50

Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 51

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 53

CODA-001 - Drug Profile 54

CVBT-141B - Drug Profile 56

Cyndacel-M - Drug Profile 58

daprodustat - Drug Profile 60

diperoxochloric acid - Drug Profile 63

EG-Decorin - Drug Profile 67

epidermal growth factor biosimilar - Drug Profile 68

EscharEx - Drug Profile 69

esmolol hydrochloride - Drug Profile 72

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 73

Granexin - Drug Profile 74

Heberprot-P - Drug Profile 76

IMSP-001 - Drug Profile 77

Ipoxyn - Drug Profile 78

IZN-6D4 - Drug Profile 79

MT-003 - Drug Profile 80

NAS-911 - Drug Profile 81

Neovasculgen - Drug Profile 83

Nu-2 - Drug Profile 84

Nu-3 - Drug Profile 85

ON-101 - Drug Profile 87

OTI-1501 - Drug Profile 89

PDA-002 - Drug Profile 90

PP-2351 - Drug Profile 91

Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 92

RG-7880 - Drug Profile 93

rusalatide acetate - Drug Profile 94

SER-190 - Drug Profile 98

sodium nitrite SR - Drug Profile 99

Statmicoll - Drug Profile 101

Stempeucel - Drug Profile 102

TOPN-53 - Drug Profile 105

TP-102 - Drug Profile 106

V-10 - Drug Profile 107

V-2248 - Drug Profile 108

VM-202 - Drug Profile 109

VTI-1000 Series - Drug Profile 113

VTI-3000 Series - Drug Profile 114

Diabetic Foot Ulcers - Dormant Projects 115

Diabetic Foot Ulcers - Discontinued Products 118

Diabetic Foot Ulcers - Product Development Milestones 119

Featured News & Press Releases 119

Appendix 128

Methodology 128

Coverage 128

Secondary Research 128

Primary Research 128

Expert Panel Validation 128

Contact Us 128

Disclaimer 129

List of Tables

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Diabetic Foot Ulcers – Pipeline by ANP Technologies Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by Anterogen Co Ltd, H1 2017

Diabetic Foot Ulcers – Pipeline by Boston Therapeutics Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by CardioVascular BioTherapeutics Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by Celgene Corp, H1 2017

Diabetic Foot Ulcers – Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by CytoTools AG, H1 2017

Diabetic Foot Ulcers – Pipeline by EyeGene Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by FirstString Research Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by Genentech Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by GlaxoSmithKline Plc, H1 2017

Diabetic Foot Ulcers – Pipeline by Human Stem Cells Institute, H1 2017

Diabetic Foot Ulcers – Pipeline by Izun Pharmaceuticals Corp, H1 2017

Diabetic Foot Ulcers – Pipeline by Lakewood-Amedex Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by MediWound Ltd, H1 2017

Diabetic Foot Ulcers – Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Diabetic Foot Ulcers – Pipeline by Oneness Biotech Co Ltd, H1 2017

Diabetic Foot Ulcers – Pipeline by Osiris Therapeutics Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by Pherecydes Pharma SA, H1 2017

Diabetic Foot Ulcers – Pipeline by RMB-Research GmbH, H1 2017

Diabetic Foot Ulcers – Pipeline by Serodus ASA, H1 2017

Diabetic Foot Ulcers – Pipeline by Stempeutics Research Pvt Ltd, H1 2017

Diabetic Foot Ulcers – Pipeline by Stratatech Corp, H1 2017

Diabetic Foot Ulcers – Pipeline by TechnoPhage SA, H1 2017

Diabetic Foot Ulcers – Pipeline by Theravasc Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by Topadur Pharma AG, H1 2017

Diabetic Foot Ulcers – Pipeline by USV Pvt Ltd, H1 2017

Diabetic Foot Ulcers – Pipeline by viDA Therapeutics Inc, H1 2017

Diabetic Foot Ulcers – Pipeline by ViroMed Co Ltd, H1 2017

Diabetic Foot Ulcers – Dormant Projects, H1 2017

Diabetic Foot Ulcers – Dormant Projects, H1 2017 (Contd..1), H1 2017

Diabetic Foot Ulcers – Dormant Projects, H1 2017 (Contd..2), H1 2017

Diabetic Foot Ulcers – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports